Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 57

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 57
---
 we enter into agreements with a licensing or collaboration partner for the development and commercialization of our product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those collaborations.

We expect a material amount
of our revenue in the future will be derived from licensing or collaboration agreements with other biopharmaceutical companies, research
institutes and universities and similar agreements. We may enter into additional agreements with a licensing or collaboration partner
for the development and commercialization of certain of our product candidates. If we enter into such agreements, we will have limited
control over the amount and timing of resources that our partners will dedicate to the development or commercialization of our product
candidates. Our ability to generate revenues from these arrangements will depend on any future licensing partners’ ability to successfully
perform the functions assigned to them in these arrangements. In addition, any future licensing or collaboration partner may have the
right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon
the expiration of the agreed upon terms.

Agreements involving our product
candidates pose a number of risks, including:

| • | partners have significant discretion in determining the efforts and resources that they will apply to 
 these matters;                                                                                        |

| • | partners may not perform their obligations as expected; |

| • | partners may not pursue development and commercialization of our product candidates or may elect not to                                     
 continue or renew development or commercialization programs, based on clinical trial results, changes in their strategic focus or available 
 funding or external factors, such as an acquisition, that divert resources or create competing priorities;                                  |

| • | partners may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical                                       
 trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical 
 testing;                                                                                                                                     |

| • | a partner with marketing and distribution rights to one or more products may not commit sufficient resources 
 to the marketing and distribution of such product or products;                                               |

| • | disagreements with partners, including disagreements over proprietary rights, contract interpretation                                          
 or the preferred course of development, might cause delays or termination of the research, development or commercialization of product         
 candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, 
 any of which would be time-consuming and expensive;                                                                                            |

| • | partners may not properly maintain or defend our intellectual property rights or may use our